

DAFTAR PUSTAKA

- 2019 Antibiotic Resistance Threats Report | CDC.* (n.d.). Retrieved October 16, 2023, from <https://www.cdc.gov/drugresistance/biggest-threats.html>
- Abbas, H. A., El-Ganiny, A. M., & Kamel, H. A. (2018). Phenotypic and genotypic detection of antibiotic resistance of *Pseudomonas aeruginosa* isolated from urinary tract infections. *African Health Sciences*, 18(1), 11–21. <https://doi.org/10.4314/ahs.v18i1.3>
- Allesen-Holm, M., Barken, K. B., Yang, L., Klausen, M., Webb, J. S., Kjelleberg, S., Molin, S., Givskov, M., & Tolker-Nielsen, T. (2006). A characterization of DNA release in *Pseudomonas aeruginosa* cultures and biofilms. *Molecular Microbiology*, 59(4), 1114–1128. <https://doi.org/10.1111/j.1365-2958.2005.05008.X>
- Banjare, B., & Barapatre, R. (2015). International Journal of Biomedical Research Incidence of carbapenem-resistant *pseudomonas aeruginosa* in clinical samples. *International Journal of Biomedical Research*, 6(08), 6. <https://doi.org/10.7439/ijbr>
- Bavasheh, N., & Karmostaji, A. (2017). Antibiotic Resistance Pattern and Evaluation of blaOXA-10, blaPER-1, blaVEB, blaSHV Genes in Clinical Isolates of *Pseudomonas aeruginosa* Isolated from Hospital in South of Iran in 2014-2015. *Infection Epidemiology and Microbiology*, 3(1), 1–5. <https://doi.org/10.18869/modares.iem.3.1.1>
- Bbosa, G. S., Mwebaza, N., Odda, J., Kyegombe, D. B., & Ntale, M. (2014). Antibiotics/antibacterial drug use, their marketing and promotion during the post-antibiotic golden age and their role in emergence of bacterial resistance. *Health*, 2014(05), 410–425. <https://doi.org/10.4236/HEALTH.2014.65059>
- Botelho, J., Grosso, F., & Peixe, L. (2019). Antibiotic resistance in *Pseudomonas aeruginosa* – Mechanisms, epidemiology and evolution. *Drug Resistance Updates*, 44. <https://doi.org/10.1016/j.drup.2019.07.002>
- Campana, E. H., Xavier, D. E., Petrolini, F. V. B., Cordeiro-Moura, J. R., Araujo, M. R. E. de, & Gales, A. C. (2017). Carbapenem-resistant and cephalosporin-susceptible: a worrisome phenotype among *Pseudomonas aeruginosa* clinical isolates in Brazil. *Brazilian Journal of Infectious Diseases*, 21(1), 57–62. <https://doi.org/10.1016/J.BJID.2016.10.008>
- Carbapenem-resistant *Pseudomonas aeruginosa* (CRPA) - Epidemiology.* (2018). <https://www.vdh.virginia.gov/epidemiology/epidemiology-fact-sheets/carbapenem-resistant-pseudomonas-aeruginosa-crpa/>
- CDC. (2019a). *MULTIDRUG-RESISTANT PSEUDOMONAS AERUGINOSA*. www.cdc.gov/hai/organisms/pseudomonas.html
- CDC. (2019b). *Pseudomonas aeruginosa Infection _ HAI _ CDC. Hospital Acquired Infections*.

- Dekimpe, V., & Déziel, E. (2009). Revisiting the quorum-sensing hierarchy in *Pseudomonas aeruginosa*: The transcriptional regulator RhIR regulates LasR-specific factors. *Microbiology*, 155(3), 712–723.
<https://doi.org/10.1099/MIC.0.022764-0/CITE/REFWORKS>
- Diggle, S. P., & Whiteley, M. (2020). Microbe Profile: *Pseudomonas aeruginosa*: opportunistic pathogen and lab rat. *Microbiology (Reading, England)*, 166(1), 30–33. <https://doi.org/10.1099/mic.0.000860>
- Duineveld, B. M., Kowalchuk, G. A., Keijzer, A., Van Elsas, J. D., & Van Veen, J. A. (2001). Analysis of bacterial communities in the rhizosphere of chrysanthemum via denaturing gradient gel electrophoresis of PCR-amplified 16S rRNA as well as DNA fragments coding for 16S rRNA. *Applied and Environmental Microbiology*, 67(1), 172–178.
<https://doi.org/10.1128/AEM.67.1.172-178.2001>
- Dzidic, S., Suskovic, J., & Kos, B. (2008). *Antibiotic Resistance Mechanisms in Bacteria: Biochemical and Genetic Aspects*. <http://www>.
- ECDC. (2019). *Surveillance of antimicrobial resistance in Europe 2018*. <https://www.ecdc.europa.eu/en/publications-data/surveillance-antimicrobial-resistance-europe-2018>
- Etebu, E., & Arikepar, I. (2016). Antibiotics: Classification and mechanisms of action with emphasis on molecular perspectives. *IJAMBR*, 4, 90–101.
- Fournier, D., Richardot, C., Müller, E., Robert-Nicoud, M., Llanes, C., Plésiat, P., & Jeannot, K. (2013). Complexity of resistance mechanisms to imipenem in intensive care unit strains of *Pseudomonas aeruginosa*. *Journal of Antimicrobial Chemotherapy*, 68(8), 1772–1780.
<https://doi.org/10.1093/JAC/DKT098>
- Gajdács, M. (2020). Carbapenem-Resistant but Cephalosporin-Susceptible *Pseudomonas aeruginosa* in Urinary Tract Infections: Opportunity for Colistin Sparing. *Antibiotics 2020, Vol. 9, Page 153*, 9(4), 153.
<https://doi.org/10.3390/ANTIBIOTICS9040153>
- Gholami, A., Majidpour, A., Talebi-Taher, M., Boustanshenas, M., & Adabi, M. (2016). PCR-based assay for the rapid and precise distinction of *Pseudomonas aeruginosa* from other *Pseudomonas* species recovered from burns patients. *Journal of Preventive Medicine and Hygiene*, 57(2), E81.
[/pmc/articles/PMC4996044/](https://pmc/articles/PMC4996044/)
- James L. S II. (2022). *M100 PERFORMANCE STANDARDS FOR ANTIMICROBIAL CLINICAL AND LABORATORY*.
- Jurado-Martín, I., Sainz-Mejías, M., & McClean, S. (2021). *Pseudomonas aeruginosa*: An Audacious Pathogen with an Adaptable Arsenal of Virulence Factors. *International Journal of Molecular Sciences 2021, Vol. 22, Page 3128*, 22(6), 3128. <https://doi.org/10.3390/IJMS22063128>

- Karam, G., Chastre, J., Wilcox, M. H., & Vincent, J. L. (2016). Antibiotic strategies in the era of multidrug resistance. *Critical Care*, 20(1). <https://doi.org/10.1186/S13054-016-1320-7>
- Karmpataki, T., Antachopoulos, C., Tsakris, A., & Roilides, E. (2018). Molecular epidemiology of carbapenem-resistant *Pseudomonas aeruginosa* in an endemic area: comparison with global data. *European Journal of Clinical Microbiology and Infectious Diseases*, 37(7), 1211–1220. <https://doi.org/10.1007/S10096-018-3244-4/METRICS>
- Karpati, F., & Jonasson, J. (1996). Polymerase chain reaction for the detection of *Pseudomonas aeruginosa*, *Stenotrophomonas maltophilia* and *Burkholderia cepacia* in sputum of patients with cystic fibrosis. *Molecular and Cellular Probes*, 10(6), 397–403. <https://doi.org/10.1006/MCPR.1996.0055>
- Karuniawati, A., R Saharman, Y., & Lestari, D. C. (2013). *Detection of carbapenemase encoding genes in Enterobacteriace, Pseudomonas aeruginosa, and Acinetobacter baumanii isolated from patients at Intensive Care Unit Cipto Mangunkusumo Hospital in 2011 - PubMed*. <https://pubmed.ncbi.nlm.nih.gov/23770789/>
- Kirienko, N. V., Kirienko, D. R., Larkins-Ford, J., Wählby, C., Ruvkun, G., & Ausubel, F. M. (2013). *Pseudomonas aeruginosa* disrupts *Caenorhabditis elegans* iron homeostasis, causing a hypoxic response and death. *Cell Host & Microbe*, 13(4), 406. <https://doi.org/10.1016/J.CHOM.2013.03.003>
- Langendonk, R. F., Neill, D. R., & Fothergill, J. L. (2021). The Building Blocks of Antimicrobial Resistance in *Pseudomonas aeruginosa*: Implications for Current Resistance-Breaking Therapies. *Frontiers in Cellular and Infection Microbiology*, 11, 307. <https://doi.org/10.3389/FCIMB.2021.665759/BIBTEX>
- Laventie, B. J., Sangermani, M., Estermann, F., Manfredi, P., Planes, R., Hug, I., Jaeger, T., Meunier, E., Broz, P., & Jenal, U. (2019). A Surface-Induced Asymmetric Program Promotes Tissue Colonization by *Pseudomonas aeruginosa*. *Cell Host and Microbe*, 25(1), 140-152.e6. <https://doi.org/10.1016/j.chom.2018.11.008>
- Lob, S. H., Kazmierczak, K. M., Chen, W. T., Siddiqui, F., DeRyke, C. A., Young, K., Motyl, M. R., & Sahm, D. F. (2022). In vitro activity of ceftolozane/tazobactam against Gram-negative isolates collected from ICU patients with lower respiratory tract infections in seven Asian countries—SMART 2017–2019. *Journal of Global Antimicrobial Resistance*, 29, 527–533. <https://doi.org/10.1016/J.JGAR.2021.11.011>
- Mahon, C. R., & Lehman, D. C. (2019). Textbook of Diagnostic Microbiology, Sixth Edition. In *Textbook of Diagnostic Microbiology*. <http://evolve.elsevier.com/Mahon/microbiology/YOU'VEJUSTPURCHASED>
- Mahon, C. R., Lehman, D. C., cm, M., & Associate Professor, S. (2019). *Textbook of Diagnostic Microbiology 6th ed.*
- Mavrodi, D. V., Bonsall, R. F., Delaney, S. M., Soule, M. J., Phillips, G., & Thomashow, L. S. (2001). Functional Analysis of Genes for Biosynthesis of

- Pyocyanin and Phenazine-1-Carboxamide from *Pseudomonas aeruginosa* PAO1. *Journal of Bacteriology*, 183(21), 6454.
<https://doi.org/10.1128/JB.183.21.6454-6465.2001>
- Meng, L., Cao, X., Li, C., Li, J., Xie, H., Shi, J., Han, M., Shen, H., & Liu, C. (2023). Housekeeping gene stability in *Pseudomonas aeruginosa* PAO1 under the pressure of commonly used antibiotics in molecular microbiology assays. *Frontiers in Microbiology*, 14, 1140515.
<https://doi.org/10.3389/FMICB.2023.1140515/BIBTEX>
- Mohr, K. I. (2016). History of antibiotics research. *Current Topics in Microbiology and Immunology*, 398, 237–272.
https://doi.org/10.1007/82_2016_499/COVER
- Mulvey, M. R., & Simor, A. E. (2009). Antimicrobial resistance in hospitals: How concerned should we be? *Canadian Medical Association Journal*, 180(4), 408–415. <https://doi.org/10.1503/cmaj.080239>
- Park, A. J., Surette, M. D., & Khursigara, C. M. (2014). Antimicrobial targets localize to the extracellular vesicle-associated proteome of *Pseudomonas aeruginosa* grown in a biofilm. *Frontiers in Microbiology*, 5(SEP).
<https://doi.org/10.3389/FMICB.2014.00464>
- Parkins, M. D., Somayaji, R., & Waters, V. J. (2018). Epidemiology, biology, and impact of clonal *pseudomonas aeruginosa* infections in cystic fibrosis. *Clinical Microbiology Reviews*, 31(4). https://doi.org/10.1128/CMR.00019-18/SUPPL_FILE/ZCM004182642S1.PDF
- Pena, C., Cabot, G., Gómez-Zorrilla, S., Zamorano, L., Ocampo-Sosa, A., Murillas, J., Almirante, B., Pomar, V., Aguilar, M., Granados, A., Calbo, E., Rodríguez-Bão, J., Rodríguez-López, F., Tubau, F., Martínez-Martínez, L., & Oliver, A. (2015). Influence of virulence genotype and resistance profile in the mortality of *pseudomonas aeruginosa* bloodstream infections. *Clinical Infectious Diseases*, 60(4), 539–548. <https://doi.org/10.1093/cid/ciu866>
- Pseudomonas aeruginosa Infection | HAI | CDC*. (n.d.). Retrieved October 28, 2022, from <https://www.cdc.gov/hai/organisms/pseudomonas.html>
- Rossolini, G. M., & Mantengoli, E. (2008). Antimicrobial resistance in Europe and its potential impact on empirical therapy. *Clinical Microbiology and Infection*, 14(SUPPL. 6), 2–8. <https://doi.org/10.1111/j.1469-0691.2008.02126.x>
- Sader, H. S., Castanheira, M., Duncan, L. R., & Flamm, R. K. (2018). Antimicrobial Susceptibility of Enterobacteriaceae and *Pseudomonas aeruginosa* Isolates from United States Medical Centers Stratified by Infection Type: Results from the International Network for Optimal Resistance Monitoring (INFORM) Surveillance Program, 2015–2016. *Diagnostic Microbiology and Infectious Disease*, 92(1), 69–74.
<https://doi.org/10.1016/J.DIAGMICROBIO.2018.04.012>
- Schirmer, T. (1998). General and Specific Porins from Bacterial Outer Membranes. *Journal of Structural Biology*, 121(2), 101–109.
<https://doi.org/10.1006/JSBI.1997.3946>

- Schmidt, K. D., Tümmler, B., & Römling, U. (1996). Comparative genome mapping of *Pseudomonas aeruginosa* PAO with *P. aeruginosa* C, which belongs to a major clone in cystic fibrosis patients and aquatic habitats. *Journal of Bacteriology*, 178(1), 85–93. <https://doi.org/10.1128/JB.178.1.85-93.1996>
- Shen, J., Pan, Y., Fang, Y., & Sekaran, S. D. (2015). Role of the Outer Membrane Protein OprD2 in Carbapenem-Resistance Mechanisms of *Pseudomonas aeruginosa*. *PloS One*, 10(10). <https://doi.org/10.1371/JOURNAL.PONE.0139995>
- Spilker, T., Coenye, T., Vandamme, P., & LiPuma, J. J. (2004). PCR-Based Assay for Differentiation of *Pseudomonas aeruginosa* from Other *Pseudomonas* Species Recovered from Cystic Fibrosis Patients. *Journal of Clinical Microbiology*, 42(5), 2074–2079. <https://doi.org/10.1128/JCM.42.5.2074-2079.2004/ASSET/982E1BB8-F86B-4AF6-90E0-DD07D51D3FDC/ASSETS/GRAPHIC/ZJM0050441990002.JPG>
- Terzi, H. A., Kulah, C., Atasoy, A. R., & Ciftci, I. H. (2015). Investigation of OprD Porin Protein Levels in Carbapenem-Resistant *Pseudomonas aeruginosa* Isolates. *Jundishapur Journal of Microbiology*, 8(12), 25952. <https://doi.org/10.5812/JJM.25952>
- Tille, P. M. (2018). *Bailey & Scott's Diagnostic Microbiology*. <https://doi.org/10.1016/B978-0-323-35482-0.00001-5>
- Tracking Carbapenem-Resistant *Pseudomonas aeruginosa* | HAI | CDC*. (n.d.). Retrieved November 10, 2022, from <https://www.cdc.gov/hai/organisms/pseudomonas/tracking.html>
- Turk, M. (2011). Antibiotic Permeability: OprD Downregulation in *Pseudomonas aeruginosa*. *Antibiotic Permeability: OprD Downregulation in Pseudomonas Aeruginosa*, 1–6. <https://doi.org/10.13140/RG.2.2.29153.81764>
- Walkty, A., Lagace-Wiens, P., Adam, H., Baxter, M., Karlowsky, J., Mulvey, M. R., McCracken, M., & Zhanel, G. G. (2016). Antimicrobial susceptibility of 2906 *Pseudomonasaeruginosa* clinical isolates obtained from patients in Canadian hospitals over a period of 8 years: Results of the Canadian Ward surveillance study (CANWARD), 2008-2015. *Diagnostic Microbiology and Infectious Disease*, 87(1), 60–63. <https://doi.org/10.1016/J.DIAGMICROBIO.2016.10.003>
- Wang, C., Ye, Q., Jiang, A., Zhang, J., Shang, Y., Li, F., Zhou, B., Xiang, X., Gu, Q., Pang, R., Ding, Y., Wu, S., Chen, M., Wu, Q., & Wang, J. (2022). *Pseudomonas aeruginosa* Detection Using Conventional PCR and Quantitative Real-Time PCR Based on Species-Specific Novel Gene Targets Identified by Pangenome Analysis. *Frontiers in Microbiology*, 13, 820431. [https://doi.org/10.3389/FMICB.2022.820431/BIBTEX](https://doi.org/10.3389/FMICB.2022.820431)
- WHO and ECDC report: antimicrobial resistance remains a health threat in Europe*. (2022). <https://www.ecdc.europa.eu/en/news-events/who-and-ecdc-report-antimicrobial-resistance-remains-health-threat-europe>

- WHO publishes list of bacteria for which new antibiotics are urgently needed.* (2017). <https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed>
- Widmer, F., Seidler, R. J., Gillevet, P. M., Watrud, L. S., & Di Giovanni, G. D. (1998). A highly selective PCR protocol for detecting 16S rRNA genes of the genus *Pseudomonas* (*sensu stricto*) in environmental samples. *Applied and Environmental Microbiology*, 64(7), 2545–2553.
<https://doi.org/10.1128/AEM.64.7.2545-2553.1998>
- York, N., San, C., Athens, F., Madrid, L., City, M., Riedel, S., Hobden, J. A., Miller, S., Morse, S. A., Mietzner, T. A., Detrick, B., Mitchell, T. G., Sakanari, J. A., & Hotez, P. (2019). *Jawetz, Melnick & Adelberg's Medical Microbiology* 28 ed. www.mhprofessional.com.
- Zhang, Y. F., Han, K., Chandler, C. E., Tjaden, B., Ernst, R. K., & Lory, S. (2017). Probing the sRNA regulatory landscape of *P. aeruginosa*: post-transcriptional control of determinants of pathogenicity and antibiotic susceptibility. *Molecular Microbiology*, 106(6), 919.
<https://doi.org/10.1111/MMI.13857>

LAMPIRAN

Lampiran 1. Jadwal Penelitian

JADWAL PENELITIAN

No	Kegiatan	Waktu Penelitian									
		Nov	Des	Jan	Feb	Mar	Apr	Mei	Jun	Jul	Ags
1.	Seminar Proposal										
2.	Pengajuan Etik dan Ijin Penelitian										
3.	Pengambilan Sampel Isolat										
4.	Identifikasi Isolat (PCR)										
5.	Pengumpulan dan Pengolahan Data										
6.	Pembacan Hasil										

Lampiran 2. Biodata Peneliti Utama**BIODATA PENELITI UTAMA****A. Data Pribadi**

1. Nama : Arthur Hugo Makapuan
2. Tempat, tgl. lahir : Palu, 1 April 1977
3. Alamat : Perum RSUD Jailolo, Halmahera Barat, Maluku Utara
4. Kewarganegaraan : Warga Negara Indonesia

B. Riwayat Pendidikan

- Tamat SLTA tahun 1995 di SMA PSKD 4 Jakarta
- Sarjana Kedokteran (S1) tahun 2000 di Universitas Kristen Indonesia
- Profesi Dokter (dr.) tahun 2006 di Universitas Kristen Indonesia

C. Pekerjaan dan Riwayat Pekerjaan

- Jenis pekerjaan : ASN Pemda Halbar / PPDS Mikrobiologi Klinik
- NIP atau identitas lain (NIK) : 197704012009031001 / 8201010104770001
- Pangkat / Jabatan : Pembina - IVa / Dokter

Biaya Penelitian

SUMBER DAN RINCIAN BIAYA PENELITIAN

No.	Rincian Biaya Kegiatan	Jumlah (Rp)
1.	Pembuatan Proposal	250.000,-
2.	Seminar Proposal	250.000,-
3.	Etik Penelitian dan Administrasi	200.000,-
4.	Kegiatan Penelitian:	
	Pengelolaan Spesimen Sampel	10.800.000,-
	Kit PCR Multiplex (untuk 3 gen berbeda)	36.000.000,-
	Kit PCR Resistensi Karbapenem (5 gen berbeda)	19.400.000,-
	Analisis Data	1.000.000,-
	Analisis Hasil	250.000,-
	Penulisan Hasil Penelitian	250.000,-
	Seminar Hasil	250.000,-
5.	Dokumentasi dan Publikasi	15.000.000,-
TOTAL		83.650.000,-

Sumber dana penelitian ini menggunakan dana pribadi peneliti dan bantuan Pemerintah Daerah Kabupaten Halmahera Barat.

Lampiran 3. Persetujuan Komite Etik Universitas Hasanuddin

KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI
UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN
KOMITE ETIK PENELITIAN UNIVERSITAS HASANUDDIN

RSPTN UNIVERSITAS HASANUDDIN

RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR

Sekretariat : Lantai 2 Gedung Laboratorium Terpadu

JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.

Contact Person: dr. Agussalim Bukhari.,MMed,PhD, SpGK TELP. 081241850858, 0411 5780103. Fax : 0411-581431



REKOMENDASI PERSETUJUAN ETIK

Nomor : 394/UN4.6.4.5.31/ PP36/ 2023

Tanggal: 21 Juni 2023

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH23060409	No Sponsor	
Peneliti Utama	dr. Arthur Hugo	Sponsor	
Judul Peneliti	Deteksi Gen Pengkode Porin OprD pada Isolat Pseudomonas aeruginosa di Rumah Sakit Universitas Hasanuddin Makassar dan Rumah Sakit Jejaringnya		
No Versi Protokol	1	Tanggal Versi	19 Juni 2023
No Versi PSP		Tanggal Versi	
Tempat Penelitian	Rumah Sakit Universitas Hasanuddin Makassar dan Rumah Sakit Jejaringnya		
Jenis Review	<input type="checkbox"/> Exempted <input checked="" type="checkbox"/> Expedited <input type="checkbox"/> Fullboard Tanggal	Masa Berlaku 21 Juni 2023 sampai 21 Juni 2024	Frekuensi review lanjutan
Ketua KEP Universitas Hasanuddin	Nama Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)	Tanda tangan	
Sekretaris KEP Universitas Hasanuddin	Nama dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)	Tanda tangan	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Lapor SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari protokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan

Lampiran 4. Izin Dirut RSPTN UNHAS untuk Melakukan Penelitian

	ADMINISTRASI	FORMULIR 1
	Nomor : 339/07/FR1/2023	Tanggal : 5 Juli 2023
SURAT PENGANTAR PENELITIAN		

Kepada Yth.

Pembimbing/pendamping,

Bapak Syafri S.,

Dengan ini menerangkan bahwa peneliti/mahasiswa berikut ini :

Nama : Arthur Hugo

NIM : C195192003

Institusi : Dept. Mikrobiologi Klinik Fakultas Kedokteran UNHAS

Akan melakukan pengambilan data/ analisa bahan hayati :

Pada tanggal : 10 Juli 2023 s/d Selesai

Jumlah subjek : ± 97 sampel

Jenis data : Data Primer

Untuk penelitian dengan judul :

“Deteksi Gen Pengkode Porin OprD pada Isolat Pseudomonas aeruginosa di Rumah Sakit Pendidikan Universitas Hasanuddin Makassar”

Harap dilakukan pembimbingan dan pendampingan seperlunya. Terima Kasih.

Staf Administrasi,




Andi Fidyah Septiani

Catatan : Proses penggerjaan dilakukan oleh peneliti, Pendamping hanya mendampingi.

Jika pengambilan data telah selesai, di wajibkan bagi pendamping/pembimbing;

1. Membubuh paraf dan tanggal selesai pengambilan data di formulir ini,
2. Mengisi jumlah alat dan bahan habis pakai yang digunakan peneliti pada form tarif penggunaan alat dan bahan,
3. Mengembalikan formulir yang sudah lengkap ke staf administrasi.

Lampiran 5. Izin Dirut RSUP Wahidin Sudirohusodo untuk Melakukan Penelitian



Nomor : DP.04.03/D.XIX.2/13999/2023
Hal : Izin Penelitian

20 Juli 2023

**Yth. Ketua Program Studi Mikrobiologi Klinik
Fakultas Kedokteran Universitas Hasanuddin**

Sehubungan dengan surat saudara nomor **12565/UN4.6.8/PT.01.04/2023**, tertanggal **29 Mei 2023**, hal **Permohonan Izin Penelitian**, dapat kami fasilitasi dan memberikan izin pelaksanaan penelitian kepada:

Nama	: dr. Arthur Hugo
NIM	: C195192003
Prog. Pend.	: MPPDS Mikrobiologi Klinik
No. HP	: 082189753958
Judul	: Deteksi Gen Pengkode Porin OprD pada Isolat Pseudomonas Aeruginosa di RSUP Dr. Wahidin Sudirohusodo Makassar
Jangka Waktu	: Tiga Bulan Setelah Surat ini di Keluarkan
Lokasi	: Inst. Rekam Medik; Laboratorium Patologi Klinik

dengan ketentuan sebagai berikut :

1. Sesuai dengan peraturan dan ketentuan penelitian yang berlaku di lingkup RSUP Dr Wahidin Sudirohusodo
2. Sebelum meneliti, peneliti wajib melapor kepada Pengawas Penelitian di masing-masing unit yang menjadi lokasi penelitian
3. Pelaksanaan penelitian tidak mengganggu proses pelayanan serta mendukung upaya peningkatan mutu pelayanan dan keselamatan pasien
4. Pemeriksaan penunjang, BHP dan lain-lain yang digunakan dalam penelitian, menjadi tanggung jawab peneliti, tidak dibebankan kepada pasien ataupun RS
5. Peneliti melaporkan proses penelitian secara periodik serta hasil penelitian di akhir waktu penelitian
6. Mencantumkan nama RSUP Dr Wahidin Sudirohusodo sebagai afiliasi institusi dalam naskah dan publikasi penelitian
7. Surat Keterangan Selesai Penelitian menjadi salah satu syarat untuk mengikuti Seminar Hasil Penelitian
8. Bukti Penyerahan Skripsi/Thesis/Disertasi ke RSUP Dr Wahidin Sudirohusodo menjadi syarat penyelesaian studi

Mohon dapat dipastikan agar ketentuan tersebut dipenuhi peneliti sebelum menyelesaikan studi di institusi saudara. Atas perhatian dan Kerjasama yang baik, diucapkan terima kasih.

a.n. Direktur Utama
Plt. Direktur Sumber Daya Manusia,
Pendidikan dan Penelitian,



Ridhayani B, SKM, M.Kes
NIP197110271997032001

Tembusan:

1. Kepala Instalasi Rekam Medik
2. Kepala Instalasi Laboratorium
3. Kepala Sub Instalasi Laboratorium Patologi Klinik

Lampiran 6. Hasil BLAST Primer Gen 16S rRNA *Pseudomonas aeruginosa*

Hasil Blast Primer 16S rRNA *P. aeruginosa*

dr. Arthur Hugo

Referensi Jurnal :

PCR-Based Assay for Differentiation of *Pseudomonas aeruginosa* from Other *Pseudomonas* Species Recovered from Cystic Fibrosis Patients

Theodore Spilker, Tom Coenye, Peter Vandamme, and John J. LiPuma
 (Department of Pediatrics and Communicable Diseases, University of Michigan Medical School, Ann Arbor, Michigan, 48109, and Laboratorium voor Microbiologie, Universiteit Gent, Ghent)

PA-SS-F : 5' – GGGGGATCTTCGGACCTCA - 3'

PA-SS-R : 5' – TCCTTAGAGTGCCCACCCG - 3'

- Showing 956 bp region from base 5037419 to 5038374.
- Due to the large size of this record, sequence and annotated features are not shown. Use the "Customize view" panel to change the display.
-

***Pseudomonas aeruginosa* strain HS_121 chromosome, complete genome**

GenBank: CP104565.1

```

LOCUS      CP104565          956 bp  DNA  linear BCT 18-OCT-2022
DEFINITION Pseudomonas aeruginosa strain HS_121 chromosome, complete genome.
ACCESSION CP104565 REGION: 5037419..5038374
VERSION    CP104565.1
DBLINK     BioProject: PRJNA793523
           BioSample: SAMN24562916
KEYWORDS   .
SOURCE     Pseudomonas aeruginosa
ORGANISM   Pseudomonas aeruginosa
Bacteria; Proteobacteria; Gammaproteobacteria; Pseudomonadales;
           Pseudomonadaceae; Pseudomonas.

```

REFERENCE 1 (bases 1 to 956)

AUTHORS Sun,Z.

TITLE Dissecting the genotypic features of a fluoroquinolone-resistant *Pseudomonas aeruginosa* ST316 sublineage causing ear infections in Shanghai, China

JOURNAL Unpublished

REFERENCE 2 (bases 1 to 956)

AUTHORS Sun,Z.

TITLE Direct Submission

JOURNAL Submitted (01-JAN-2022) Institute of Antibiotics, Huashan Hospital, Fudan University, No 12 M Urumqi Road, Jingan district, Shanghai, Shanghai 200040, China

COMMENT The annotation was added by the NCBI Prokaryotic Genome Annotation Pipeline (PGAP). Information about PGAP can be found here:

https://www.ncbi.nlm.nih.gov/genome/annotation_prok/

##Genome-Assembly-Data-START##

Assembly Method :: Canu v. 2.1

Genome Representation :: Full

Expected Final Version :: Yes

Genome Coverage :: 100x

Sequencing Technology :: PacBio RSII; Illumina NovaSeq

##Genome-Assembly-Data-END##

##Genome-Annotation-Data-START##

Annotation Provider :: NCBI

Annotation Date :: 09/16/2022 16:46:52

Annotation Pipeline :: NCBI Prokaryotic Genome

Annotation Pipeline (PGAP)

Annotation Method :: Best-placed reference protein set; GeneMarkS-2+

Annotation Software revision :: 6.2

Features Annotated :: Gene; CDS; rRNA; tRNA; ncRNA; repeat_region

Genes (total) :: 6,640

CDSs (total) :: 6,560

Genes (coding) :: 6,480

CDSs (with protein) :: 6,480

Genes (RNA) :: 80

rRNAs :: 4, 4, 4 (5S, 16S, 23S)

complete rRNAs :: 4, 4, 4 (5S, 16S, 23S)

tRNAs :: 64

ncRNAs :: 4

```

Pseudo Genes (total) :: 80
CDSs (without protein) :: 80
Pseudo Genes (ambiguous residues) :: 0 of 80
Pseudo Genes (frameshifted) :: 38 of 80
Pseudo Genes (incomplete) :: 47 of 80
Pseudo Genes (internal stop) :: 4 of 80
Pseudo Genes (multiple problems) :: 8 of 80
##Genome-Annotation-Data-END##


FEATURES Location/Qualifiers
source 1..956
/organism="Pseudomonas aeruginosa"
/mol_type="genomic DNA"
/strain="HS_121"
/isolation_source="ear swabs"
/host="Homo sapiens"
/db_xref="taxon:287"
/country="China: Shanghai"
/lat_lon="31.23 N 121.45 E"
/collection_date="2020"
/collected_by="Baixing Ding"

gene complement(<1..>956)
/locus_tag="N5874_23400"

rRNA complement(<1..>956)
/locus_tag="N5874_23400"
/product="16S ribosomal RNA"
/inference="COORDINATES: nucleotide
motif:Rfam:14.4:RF00177"
/inference="COORDINATES: profile:INFERNAL:1.1.1"
/note="Derived by automated computational analysis using
gene prediction method: cmsearch."
/db_xref="RFAM:RF00177"


ORIGIN
//
>CP104565.1:5037419-5038374 Pseudomonas aeruginosa strain HS_121 chromosome,
complete genome

PA-SS-R
TCCTTAGAGTGCCCACCCG
TCCTTAGAGTGCCCACCCGAGGTGCTGGTAACTAAGGACAAGGGTTGCGCTCGTTA
CGGGACTTAACCCA
ACATCTCACGACACCGAGCTGACGACAGCCATGCAGCACCTGTGCTGAGTTCCCGA
AGGCACCAATCCAT
CTCTGGAAAGTTCTCAGCATGTCAAGGCCAGGTAAGGTTCTCGCGTTGCTTCGAAT
TAAACCACATGCT
CCACCGCTTGTGCGGGCCCCGTCAATTGAGTTAACCTTGCAGGCCGTACT
CCCCAGGCGGTG

```

ACTTATCGCGTTAGCTGCGCCACTAAGATCTCAAGGATCCAACGGCTAGTCGACAT
CGTTTACGGCGTG
GACTACCAGGGTATCTAATCCTGTTGCTCCCCACGCTTCGCACCTCAGTGTCACT
ATCAGTCCAGGTG
GTCGCCTCGCCACTGGTGTTCCTCCTATATCTACGCATTCACCGCTACACAGGA
AATTCCACCACCC
TCTACCGTACTCTAGCTCAGTAGTTGGATGCAGTCCCAGGTTGAGCCCCGGGGAT
TTCACATCCA
TGCTGAACCACCTACGCGCGCTTACGCCAGTAATTCCGATTAACGCTTGCACCC
TCGTATTACCGCG
GCTGCTGGCACGAAGTTAGCCGGTGCCTATTCTGTTGTAACGTCAAAACAGCAAG
GTATTAACTTACTG
CCCTTCCTCCCAACTTAAAGTGCTTACAATCCGAAGACCTTCTTCACACACGCGGC
ATGGCTGGATCAG
GCTTCGCCCATGTCCAATATTCCCCACTGCTGCCTCCGTAGGAGTCTGGACCGT
GTCTCAGTTCCAG
TGTGACTGATCATCCTCTCAGACCAGTTACGGATCGTCGCCTGGTAGGCCTTACC
CCACCAACTAGCT

PA-SS-F

GGGGGATCTCGGACCTCA
CCCCCTAGAAGCCTGGAGT
TGAGGTCCGAAGATCCCC

AATCCGACCTAGGCTCATCTGATAGCGTGAGGTCCGAAGATCCCC

Lampiran 7. Hasil BLAST Primer Gen oprD *Pseudomonas aeruginosa*

Hasil Blast Primer Gen oprD *Pseudomonas aeruginosa*

dr. Arthur Hugo

Referensi Jurnal

Phenotypic and genotypic detection of antibiotic resistance of *Pseudomonas aeruginosa* isolated from urinary tract infections

Hisham A Abbas, Amira M El-Ganiny, Hend A Kamel (Microbiology and Immunology Department, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt., Microbiology Department, Faculty of Pharmacy and Pharmaceutical Industries, Sinai University, Kantara, Egypt)

OprD-F : 5' – GCTCGACCTCGAGGCAGGCCA – 3'

OprD-R : 5' – CCAGCGATTGGTCGGATGCCA – 3'

- Showing 242 bp region from base 516 to 757.

***Pseudomonas aeruginosa* strain KB-PA-F19 outer membrane porin OprD (oprD) gene, complete cds**

GenBank: OL372283.1

LOCUS OL372283 242 bp DNA linear BCT 10-MAY-2022

DEFINITION *Pseudomonas aeruginosa* strain KB-PA-F19 outer membrane porin OprD (oprD) gene, complete cds.

ACCESSION [OL372283](#) REGION: 516..757

VERSION OL372283.1

KEYWORDS .

SOURCE *Pseudomonas aeruginosa*

ORGANISM [Pseudomonas aeruginosa](#)

Bacteria; Proteobacteria; Gammaproteobacteria; Pseudomonadales; Pseudomonadaceae; *Pseudomonas*.

REFERENCE 1 (bases 1 to 242)

AUTHORS Fang,Y., Baloch,Z., Zhang,W., Hu,Y., Zheng,R., Song,Y., Tai,W. and Xia,X.

TITLE Emergence of Carbapenem-Resistant ST244, ST292, and ST2446 Pseudomonas aeruginosa Clones in Burn Patients in Yunnan Province

JOURNAL Infect Drug Resist 15, 1103-1114 (2022)

PUBMED [35321081](#)

REMARK Publication Status: Online-Only

REFERENCE 2 (bases 1 to 242)

AUTHORS Fang,Y.

TITLE Direct Submission

JOURNAL Submitted (25-OCT-2021) Faculty of Life Science and Technology, Kunming University of Science and Technology, Jingming road, Kunming City, Yunnan 650500, China

COMMENT ##Assembly-Data-START##

Sequencing Technology :: Sanger dideoxy sequencing

##Assembly-Data-END##

FEATURES Location/Qualifiers

source 1..242

/organism="Pseudomonas aeruginosa"

/mol_type="genomic DNA"

/strain="KB-PA-F19"

/isolation_source="hospital"

/db_xref="taxon:[287](#)"

/country="China"

/note="identical sequence found in strains KB-PA-F19, KB-PA-F7 and KB-PA-F24; sequence type 244; ST244"

gene <1..>242

/gene="oprD"

CDS <1..>242

/gene="oprD"

/codon_start=2

/transl_table=[11](#)

/product="outer membrane porin OprD"

/protein_id="[UPX85317.1](#)"

/translation="MKVMKWSAIALALAVSAGSTQFAVADAFVSDQAEAKGFIEDSSLDL

LLRNYYFNRDGKSGSGDRVDWTQGFLTTYESGFTQGTVGFGVDAFGYLGLKLDGTSD

K

TGTGNLPVMNDGKPRDDYSRAGGAVKVRISKMLKGEMQPTAPVFAAGGSRLFPQT
A

TGFQLQSSEFGLDLEAGHFTEGKEPTTVKSRGELYATYAGETAKSADFIGGRYAITD

NLSASLYGAELEDIYRQYYLNSNYTIPLASDQSLGFDFNIYRTNDEGKAKAGDISNTT

WSLAAAYTLDAHTFLAYQKVHGDQPFDYIGFGRNGSGAGGDSIFLANSVQYSDFNGP

GEKSWQARYDLNLASYGVPGLETFMVRINGKDIDGTKMSDNNVGYKNYGYGEDGKHH
E

TNLEAKYVVQSGPAKDLSFRIRQAWHRANADQGEGDQNEFRLIVDYPLSIL"
ORIGIN

OprD-F

gctcgacctc gaggcaggcc a
1 gctcgacctc gaggcaggcc a cttcaccga gggcaaggag ccgaccacccg tcaaatcgcg
61 tggcgaaactc tatgccacct acgcaggcga gaccgccaag agcgccgatt tcattggggg
121 ccgctacgca atcaccgata acctcagcgc ctccctgtac ggcgccgaac tcgaagacat


OprD-R


ccagcgatt ggtcgatgc
 ggtcgctaa ccagcctacg
tggcatccg accaatcgct
181 ctatcgccag tattacctga acagcaacta caccatccca c tggcatccg accaatcgct
 ca
 gt
 gg
241 gg

Lampiran 8. Data penelitian

KODE	UMUR	JK	SAMPEL	BEDAH NON-BEDAH	HASIL UJI ANTIBIOTIK SEBELUMNYA												MacConkey Katalase	TES BIOKIMIA	LSS RNA Perc/tgnsa	LSS RNA optD P		
					AN	CN	ATM	PEP	CAZ	CIP	LVK	IMI	MEM	PIP/TAZ	TSI	SIN	MIR	VP	CITRAT			
A1	2	L	Urine	NB	S	S	S	S	S	S	S	S	S	+	+	+	+	-	+	+	+	
A2	46	L	Sputum	NB	S	-	I	R	R	R	S	S	R	+	+	+	+	-	+	+	+	
A3	76	L	ETT	B	S	S	S	S	S	S	S	S	S	+	+	+	+	-	+	+	+	
A4	57	L	ETT	B	S	S	S	R	I	R	R	R	I	+	+	+	+	-	+	+	+	
A5	40	P	Bilasan bronchus	NB	S	S	S	S	S	S	S	S	S	+	+	+	+	-	+	+	+	
A6	63	P	Bilasan bronchus	NB	R	R	R	R	R	R	R	R	R	+	+	+	+	-	+	+	+	
A7	32	L	Sputum	NB	R	S	R	R	S	R	R	R	S	+	+	+	+	-	+	+	+	
A8	59	L	Sputum	NB	S	S	S	S	S	I	I	S	S	+	+	+	+	-	+	+	+	
A9	50	L	Sputum	NB	S	R	I	R	I	R	R	R	I	+	+	+	+	-	+	+	+	
A10	51	L	Sputum	NB	S	R	I	R	I	R	R	R	I	+	+	+	+	-	+	+	+	
A11	48	P	Shunt peritoneal	NB	S	S	S	S	S	-	S	S	S	+	+	+	+	-	+	+	+	
A13	49	P	Urine	NB	S	S	S	S	S	-	S	S	S	+	+	+	+	-	+	+	+	
A16	43	P	Swab dasar luka	B	S	S	S	S	S	-	S	S	S	+	+	+	+	-	+	+	+	
A17	57	P	Cairan vitreous OS	B	S	S	S	S	S	-	S	S	S	+	+	+	+	-	+	+	+	
A18	56	P	Swab fistula	B	S	S	R	S	R	I	-	R	I	+	+	+	+	-	+	+	+	
A19	64	P	Sputum	NB	S	S	-	-	R	-	S	R	R	+	+	+	+	-	+	+	+	
A20	1	L	Feces	NB	S	S	R	S	S	S	S	S	S	+	+	+	+	-	+	+	+	
A21	58	L	Bilasan bronchus	NB	S	S	-	-	S	R	R	S	S	+	+	+	+	-	+	+	+	
A22	39	L	Sputum	NB	S	R	S	S	S	R	-	S	S	+	+	+	+	-	+	+	+	
A23	29	L	Jaringan	B	R	R	R	R	R	R	R	R	R	+	+	+	+	-	+	+	+	
A24	56	L	PUS	B	S	S	I	R	S	I	R	R	R	S	+	+	+	-	+	+	+	
A25	26	L	ETT	NB	I	R	I	R	R	R	R	R	I	+	+	+	+	-	+	+	+	
A26	46	L	Bilasan bronchus	NB	S	S	I	S	S	I	R	S	S	S	+	+	+	+	-	+	+	
A27	40	L	Jaringan	B	S	I	R	R	R	R	R	R	R	+	+	+	+	-	+	+	+	
A28	62	P	Sputum aspirat	NB	S	S	I	R	S	-	S	R	R	I	+	+	+	+	-	+	+	
A30	24	P	Sputum	NB	S	S	S	S	S	-	S	S	S	+	+	+	+	-	+	+	+	
A31	45	P	Sputum	NB	S	S	S	S	S	-	S	S	S	+	+	+	+	-	+	+	+	
A32	71	P	Swab Pus	NB	S	S	S	S	S	-	S	S	S	+	+	+	+	-	+	+	+	
A33	73	P	Sputum	NB	S	I	S	S	R	-	S	S	S	+	+	+	+	-	+	+	+	
A34	62	P	Jaringan	B	S	S	I	I	S	-	S	I	I	S	+	+	+	+	-	+	+	
A35	55	L	Sputum suction	NB	S	S	S	S	S	-	S	S	S	S	+	+	+	+	-	+	+	
A36	48	P	Urine	NB	S	S	I	S	S	-	S	S	S	S	+	+	+	+	-	+	+	
A37	61	L	Sputum	NB	R	R	I	R	R	R	R	R	I	+	+	+	+	-	+	+	+	
A38	27	P	Sputum	NB	S	S	R	I	S	S	S	S	S	+	+	+	+	-	+	+	+	
A39	2	L	ETT	NB	S	S	R	S	I	R	R	S	S	S	+	+	+	-	+	+	+	
A40	56	L	Sputum	NB	S	S	R	S	S	S	S	S	S	S	+	+	+	-	+	+	+	
A41	56	P	Sputum ETT	NB	S	S	R	R	I	R	R	R	R	+	+	+	+	-	+	+	+	
A42	48	L	Cairan pleura	NB	I	R	I	R	R	R	R	R	R	S	+	+	+	-	+	+	+	
A43	4	P	Pus	B	S	S	S	R	I	S	I	R	R	S	+	+	+	-	+	+	+	
A44	53	L	Sputum	NB	S	S	I	S	S	S	S	I	S	S	+	+	+	-	+	+	+	
A45	11	L	Pus	NB	S	S	I	S	S	S	R	S	S	S	+	+	+	-	+	+	+	
A46	61	P	Urine	NB	S	S	S	S	S	S	S	S	S	S	+	+	+	-	+	+	+	
A47	71	L	Bilasan bronchus	NB	S	S	S	S	S	S	S	S	S	S	+	+	+	-	+	+	+	
A48	1	P	Pus	B	S	S	S	S	S	S	I	S	S	S	+	+	+	-	+	+	+	
A49	81	L	Sputum	NB	S	S	S	S	S	S	S	S	S	S	+	+	+	-	+	+	+	
A50	51	L	Pus	B	S	S	S	S	S	S	S	S	S	S	+	+	+	-	+	+	+	
A53	10	P	Pus	B	S	S	S	S	S	S	S	S	S	S	+	+	+	-	+	+	+	
A54	24	P	Sputum	NB	S	S	I	S	S	S	S	S	S	S	+	+	+	-	+	+	+	
A55	1	L	ETT	NB	S	S	R	S	S	S	S	S	S	S	+	+	+	-	+	-	-	
A56	1	P	Feces	NB	S	S	S	S	S	S	S	S	S	S	+	+	+	-	+	+	+	
A57	8	L	Feces	NB	S	S	S	S	S	S	R	S	S	S	+	+	+	-	+	+	+	
A58	L	ETT	NB	S	S	I	S	S	S	S	S	S	S	S	+	+	+	-	+	+	+	
A59	29	P	Bilasan bronchus	NB	S	S	S	S	S	S	S	S	S	S	S	+	+	+	-	+	+	+
A60	63	L	Sputum ETT	B	I	R	I	R	R	R	R	R	R	S	+	+	+	-	+	+	+	
A61	23	L	Sputum	NB	S	S	S	S	S	S	S	S	S	S	+	+	+	-	+	+	+	
A62	27	L	Jaringan	B	S	S	I	R	S	S	S	S	I	+	+	+	+	-	+	+	+	
A65	1	P	Darah	NB	S	S	S	S	S	S	S	S	S	S	+	+	+	-	+	+	+	
A66	21	L	Jaringan	B	S	S	S	S	S	S	S	S	S	S	+	+	+	-	+	+	+	
A67	27	L	Bilasan bronchus	NB	R	R	R	R	R	R	R	R	R	R	+	+	+	-	+	+	+	
A68	39	L	Pus	B	S	S	R	R	S	S	S	S	S	S	+	+	+	-	+	+	+	
A69	76	L	Sputum	NB	S	S	S	S	S	S	S	S	S	S	+	+	+	-	+	+	+	
A70	46	L	Bilasan bronchus	NB	S	S	R	R	S	S	S	S	S	S	+	+	+	-	+	+	+	
A71	27	L	Jaringan	B	S	S	I	R	R	S	S	S	S	I	+	+	+	-	+	+	+	
A72	54	L	Darah	NB	S	S	S	S	S	S	S	S	S	S	+	+	+	-	+	+	+	
A73	1	L	Pus	B	S	S	S	S	S	S	S	S	S	S	+	+	+	-	+	+	+	
A74	61	L	Pus	NB	S	S	R	I	R	S	R	S	S	S	+	+	+	-	+	+	+	
A75	10	P	Sputum	B	S	S	S	S	S	S	S	S	S	S	+	+	+	-	+	+	+	
A78	51	P	Sputum	NB	S	S	S	S	S	S	S	S	S	S	+	+	+	-	+	+	+	
A79	34	L	ETT	B	R	R	R	R	R	R	R	R	R	R	+	+	+	-	+	+	+	
A80	54	L	Pus	B	S	S	R	R	S	S	I	R	R	I	+	+	+	-	+	+	+	
A81	49	L	Sputum	NB	I	R	S	S	R	R	R	R	I	+	+	+	+	-	+	+	+	
A82	2	L	ETT	NB	S	S	R	I	R	R	R	R	I	+	+	+	+	-	+	+	+	
A83	34	L	Bilasan bronchus	NB	S	S	S	S	S	S	S	S	S	S	+	+	+	-	+	+	+	
A85	7	L	ETT	NB	R	R	I	R	R	R	R	R	R	R	+	+	+	-	+	+	+	
A86	72	L	Sputum	NB	S	S	R	S	S	S	S	S	S	S	+	+	+	-	+	+	+	
A87	56	L	Pus	B	I	R	R	I	R	R	R	R	I	+	+	+	+	-	+	+	+	
A90	2	L	ETT	B	S	S	I	S	S	S	S	S	S	S	+	+	+	-	+	+	+	
A92	13	L	Feces	NB	S	S	S	S	S	S	S	S	S	S	+	+	+	-	+	+	+	
A93	5	P	Jaringan	B	S	S	S	S	S	S	S	S	S	S	+	+	+	-	+	+	+	
A94	43	L	Sputum	NB	S	S	R	S	S	S	S	S	S	S	+	+	+	-	+	+	+	
A95	61	L	Sputum	NB	S	S	R	S	S	S	S	S	S	S	+	+	+	-	+	+	+	
A97	49	L	Jaringan	NB	B	S	S	I	R	R	S	S	S	I	+	+	+	-	+	+	+	
A99	7	L	ETT	NB	R	R	R	R	R	R	R	R	R	R	+	+	+	-	+	+	+	
A101	63	L	Sputum	NB	S	S	S	S	S	S	S	S	S	S	+	+	+	-	+	+		

Lampiran 9. Data hasil PCR gen 16S rDNA *Pseudomonas aeruginosa*





Lampiran 10. Data hasil PCR gen 16S rRNA oprD *Pseudomonas aeruginosa*

